CN105431447A - Pcsk9的小分子调节剂和其使用方法 - Google Patents

Pcsk9的小分子调节剂和其使用方法 Download PDF

Info

Publication number
CN105431447A
CN105431447A CN201480026888.4A CN201480026888A CN105431447A CN 105431447 A CN105431447 A CN 105431447A CN 201480026888 A CN201480026888 A CN 201480026888A CN 105431447 A CN105431447 A CN 105431447A
Authority
CN
China
Prior art keywords
compound
substituted
alkyl
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026888.4A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·瓜伊
谢尔登·克兰
尼古拉斯·拉尚斯
让-弗朗索瓦·基亚森
武伊·灵·长
帕特里克·拉孔贝
凯瑟琳·斯科雷
纳比尔·G·赛义达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMORCHEM HOLDINGS Inc
A Dalata Partnership Co Ltd
Original Assignee
AMORCHEM HOLDINGS Inc
A Dalata Partnership Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMORCHEM HOLDINGS Inc, A Dalata Partnership Co Ltd filed Critical AMORCHEM HOLDINGS Inc
Publication of CN105431447A publication Critical patent/CN105431447A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Crystallography & Structural Chemistry (AREA)
CN201480026888.4A 2013-03-15 2014-03-14 Pcsk9的小分子调节剂和其使用方法 Pending CN105431447A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792249P 2013-03-15 2013-03-15
US61/792,249 2013-03-15
PCT/CA2014/050255 WO2014139008A1 (en) 2013-03-15 2014-03-14 Small molecule modulators of pcsk9 and methods of use thereof

Publications (1)

Publication Number Publication Date
CN105431447A true CN105431447A (zh) 2016-03-23

Family

ID=51535727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026888.4A Pending CN105431447A (zh) 2013-03-15 2014-03-14 Pcsk9的小分子调节剂和其使用方法

Country Status (10)

Country Link
US (1) US20160031935A1 (https=)
EP (1) EP2961765A4 (https=)
JP (1) JP2016511274A (https=)
KR (1) KR20150132362A (https=)
CN (1) CN105431447A (https=)
AU (1) AU2014231330A1 (https=)
BR (1) BR112015023761A2 (https=)
CA (1) CA2905237A1 (https=)
HK (1) HK1222864A1 (https=)
WO (1) WO2014139008A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109096247A (zh) * 2018-08-15 2018-12-28 上海罕道医药科技有限公司 一种3h双吖丙啶基双取代吡啶衍生物的制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10034892B2 (en) 2014-08-21 2018-07-31 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
US20170290806A1 (en) * 2014-09-08 2017-10-12 Temple University-Of The Commonwealth System Of Higher Education PCSK9 Inhibitors and Methods of Use Thereof
EP3973958A3 (en) * 2015-03-20 2022-06-22 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
BR112018076242A2 (pt) 2016-06-24 2019-03-26 Hoffmann La Roche inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1
GB2567210B (en) 2017-10-06 2020-01-15 Rolls Royce Plc A bladed disk
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
LV15544A (lv) * 2019-07-01 2021-01-20 Latvijas Organiskās Sintēzes Institūts Jauni borskābi saturoši peptidomimētiķi kā malārijas serīna proteāzes inhibitori
WO2024163598A2 (en) * 2023-01-31 2024-08-08 Brandeis University Peptides comprising thioester groups, including depsipeptide thioesters, methods of making, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679527A (zh) * 2007-04-13 2010-03-24 诺瓦提斯公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
CN102665752A (zh) * 2009-12-22 2012-09-12 伊莱利利公司 泌酸调节肽类似物
CN102892417A (zh) * 2010-03-01 2013-01-23 欧尼斯治疗公司 用于免疫蛋白酶体抑制的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013461A1 (en) * 1996-09-24 1998-04-02 The Procter & Gamble Company Liquid laundry detergent compositions containing proteolytic enzyme and protease inhibitors
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
AU2003228793B2 (en) * 2002-04-30 2008-01-03 Trustees Of Tufts College Smart Pro-Drugs of Serine Protease Inhibitors
US8999922B2 (en) * 2012-02-16 2015-04-07 Rqx Pharmaceuticals, Inc. Linear peptide antibiotics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679527A (zh) * 2007-04-13 2010-03-24 诺瓦提斯公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
CN102665752A (zh) * 2009-12-22 2012-09-12 伊莱利利公司 泌酸调节肽类似物
CN102892417A (zh) * 2010-03-01 2013-01-23 欧尼斯治疗公司 用于免疫蛋白酶体抑制的化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109096247A (zh) * 2018-08-15 2018-12-28 上海罕道医药科技有限公司 一种3h双吖丙啶基双取代吡啶衍生物的制备方法

Also Published As

Publication number Publication date
EP2961765A4 (en) 2016-11-09
AU2014231330A1 (en) 2015-10-01
CA2905237A1 (en) 2014-09-18
HK1222864A1 (zh) 2017-07-14
KR20150132362A (ko) 2015-11-25
BR112015023761A2 (pt) 2017-07-18
WO2014139008A1 (en) 2014-09-18
JP2016511274A (ja) 2016-04-14
US20160031935A1 (en) 2016-02-04
EP2961765A1 (en) 2016-01-06

Similar Documents

Publication Publication Date Title
CN105431447A (zh) Pcsk9的小分子调节剂和其使用方法
CN110809467B (zh) Sestrin-gator2相互作用的调节剂及其用途
US11692008B2 (en) Preparation and uses of reactive oxygen species scavenger derivatives
TWI353977B (en) Novel sulphonylpyrroles
BRPI0709610A2 (pt) compostos ligantes do domìnio iap bir
JP7406556B2 (ja) Ｈｉｖ療法に有用な化合物
BRPI0617751A2 (pt) compostos de ligação do domìnio iap bir
JP2018076337A (ja) 芳香族陽イオン性ペプチドおよびその使用
CN110088120A (zh) 转谷氨酰胺酶的抑制剂
CN111356699A (zh) 活性氧清除剂的制备及用途
US20260034096A1 (en) Sirtuin 6 protein deacylase (sirt6) activators
KR20100126762A (ko) 세포내 효소 및 수용체 조절
JP2022512687A (ja) Ｃｇｒｐアンタゴニストのプロドラッグ
EP4208455A1 (en) Lzk-targeting degraders and methods of use
WO2023025861A1 (en) New vashs inhibitors, conjugates thereof and their uses as drugs or as research tools
TW201514147A (zh) Ｆｐｒ１拮抗劑的衍生物及其用途
AU2023429876A1 (en) Ptp1b/tc-ptp dual inhibitors and protein degraders
EP4058448A1 (en) Substituted hydantoinamides as adamts7 antagonists
Bhattarai et al. CNS-penetrant LMP2 Inhibitors as Potential Therapies for Age-related Macular Degeneration
CN118546122A (zh) 一类靶向降解tead的化合物及其制备方法和应用
CN116715639A (zh) 基于邻苯二胺及酰肼类靶向hdac/pd-l1双功能分子合成及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222864

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160323

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1222864

Country of ref document: HK